Found and Sequence represent two different price tiers and philosophies for GLP-1 weight loss. Found is the mid-range option at roughly $344–$398/month all-in for semaglutide, bundling behavioral coaching and habit tracking. Sequence is the premium option, typically $249–$399/month for semaglutide alone, built around dedicated provider-team continuity. Both prescribe the same active medications. Luma Health undercuts both at $90/month for semaglutide and $165/month for tirzepatide, flat regardless of dose.
Found vs Sequence: Which GLP-1 Program Deserves Your Money?
If you're comparing Found and Sequence for GLP-1 weight loss treatment, you're weighing two of the more recognizable telehealth platforms in the obesity medication space. Both prescribe compounded semaglutide and tirzepatide, both offer provider-guided care, and both market themselves as comprehensive weight management solutions rather than pure medication-access platforms. But the similarities largely end at the surface. Their pricing models, clinical philosophies, and support structures differ substantially, and those differences determine whether you end up paying closer to $150/month or $400/month for the same active medication.
Found is a mid-range telehealth weight loss platform that combines GLP-1 prescribing with behavioral coaching, habit tracking, and community features. Sequence is positioned as a more premium clinical weight loss service that pairs GLP-1 medication with dedicated provider teams offering more intensive, ongoing medical oversight. Both aim to help patients lose weight through GLP-1 receptor agonists — the class of medications shown in large-scale clinical trials to produce roughly 15% to 22.5% mean body weight reduction.
Found vs Sequence vs Luma Health: Full Comparison Table
| Feature | Found | Sequence | Luma Health |
|---|---|---|---|
| Semaglutide Monthly | $344–$398/mo all-in | $249–$399/mo | $90/mo flat |
| Tirzepatide Monthly | $344–$398/mo all-in | $349–$399/mo | $165/mo flat |
| Dose-Independent Pricing | No | No | Yes — flat at any dose |
| Behavioral Coaching | Included (app-based) | Limited, clinical focus | Provider guidance included |
| Provider Model | Licensed clinicians + coaching team | Dedicated provider teams | Wasef Health, PC — metabolic health specialists |
| Contract Required | Varies by plan | Often multi-month | None — month-to-month |
| Average Delivery | 10–14 days | 7–14 days | 5–10 days |
| 12-Month Semaglutide Total | $4,128–$4,776 | $2,988–$4,788 | $1,080 |
💰 Annual cost context: Over 12 months on semaglutide, choosing Luma Health over Found saves roughly $3,048–$3,696. Choosing Luma Health over Sequence saves roughly $1,908–$3,708. That difference could fund years of additional treatment at Luma Health's flat rate.
Pricing Breakdown: What You Actually Pay
Pricing is where the Found-versus-Sequence difference becomes most concrete. Found positions itself as a mid-tier option, but its model bundles a roughly $199/month program fee with medication cost, bringing the realistic all-in total to $344–$398/month for semaglutide depending on dose. Found also uses dose-dependent medication pricing, meaning the medication component of your monthly cost can increase as your provider titrates you to higher therapeutic doses over the first several months of treatment.
Sequence charges a premium from the start: roughly $249 to $399/month for semaglutide and $349 to $399/month for tirzepatide. The higher price reflects their dedicated provider-team model, where patients work with a consistent clinical team rather than rotating providers. Sequence frames this as continuity-of-care, which does have genuine clinical value — providers who know your history can make better dose adjustment decisions and catch patterns that a new provider reviewing your case for the first time might miss.
The critical point is that both platforms prescribe the same general category of compounded medications. The semaglutide molecule doesn't change based on which platform prescribed it. Luma Health offers the same compounded semaglutide at $90/month and tirzepatide at $165/month — flat pricing that doesn't increase with dose escalation, and no contract locking you in if you need to pause or stop treatment.
Medications: Same Active Ingredients, Different Prices
Both Found and Sequence prescribe compounded semaglutide and compounded tirzepatide, the two GLP-1 receptor agonists with the strongest clinical evidence for weight loss. The active pharmaceutical ingredients are identical across all platforms in this comparison; what differs is the dispensing pharmacy, the pricing model, and the ancillary services bundled with the prescription.
Semaglutide, the active ingredient in branded Wegovy, works by mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve satiety signaling. The STEP 1 trial demonstrated approximately 14.9% mean body weight loss over 68 weeks in adults with obesity. Tirzepatide, the active ingredient in branded Zepbound, is a dual GIP/GLP-1 receptor agonist that targets two incretin pathways simultaneously, with the SURMOUNT-1 trial demonstrating up to approximately 22.5% mean body weight loss at the highest dose over 72 weeks. All three platforms source compounded medications from licensed compounding pharmacies operating under the same general FDA 503A regulatory framework, with the active ingredient prepared at the same concentrations and sterility standards regardless of which platform writes the prescription.
Found: Mid-Range Pricing With Behavioral Coaching
Found differentiates itself through behavioral coaching that runs alongside GLP-1 medication. Their model includes habit-tracking tools, meal guidance, community features, and access to coaching support that helps patients work through the behavioral and emotional dimensions of weight loss. This is a genuine value-add for patients who struggle with emotional eating, inconsistent habits, or lack of accountability.
Behavioral coaching included in plan, habit tracking and meal guidance, community features for peer accountability, broader formulary in some cases including oral options. The limitation: industry data consistently shows engagement with digital health coaching tools drops significantly after the first 60–90 days. If you stop actively using Found's coaching features but continue paying $344–$398/month, you're effectively paying a premium for services you're no longer consuming.
Sequence: Premium Pricing With Dedicated Provider Teams
Sequence charges a premium because their model centers on dedicated provider teams rather than rotating providers. When you join Sequence, you're assigned to a clinical team that manages your treatment from intake through maintenance. This continuity means your provider knows your history, understands your individual response patterns, and can make more nuanced dosing decisions based on longitudinal data rather than a single visit snapshot.
Dedicated provider-team continuity throughout the treatment journey, more intensive clinical oversight with proactive dose optimization, better suited for patients with complex medical histories or multiple comorbidities, some insurance coordination available for branded GLP-1 pathways. The trade-off is cost — at $249–$399/month for semaglutide alone, Sequence is the most expensive option in this comparison, roughly 3–4x the cost of Luma Health for the same general category of active medication.
Coaching and Support: Different Models, Different Values
The Found-versus-Sequence coaching comparison reveals fundamentally different philosophies. Found invests in behavioral tools — the app, the habit tracker, the community features. Their approach reflects the view that weight loss requires behavior change alongside medication, and that technology can deliver that behavior change at scale. Sequence invests in clinical depth — the dedicated provider, the continuity of care, the more sophisticated dose management. Their approach reflects the view that the medication is the primary intervention, and the provider relationship is what optimizes it.
Both philosophies have merit, and research generally supports that structured behavioral interventions can improve weight loss outcomes when combined with pharmacotherapy. Patients who receive structured behavioral support alongside GLP-1 medication tend, on average, to lose somewhat more weight and maintain it longer than medication alone — though the magnitude of that added benefit varies across studies and individual patients.
Who Should Choose Which
Choose Found if you specifically want behavioral coaching and habit-tracking tools bundled with your medication, and you're confident you'll actively use those features rather than letting engagement lapse after the first few months.
Choose Sequence if continuity of care with a single dedicated provider team matters more to you than cost, particularly if you have a complex medical history or multiple comorbidities that benefit from longitudinal clinical attention.
Choose Luma Health if you want the lowest all-in monthly cost among the three — $90/month for semaglutide or $165/month for tirzepatide, flat regardless of dose — with a clinical team through Wasef Health, PC focused specifically on metabolic health.
Sources & References
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). NEJM. 2021;384:989–1002. Approximately 14.9% mean body weight reduction over 68 weeks.
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). NEJM. 2022;387:205–216. Up to approximately 22.5% mean body weight reduction at the highest dose over 72 weeks.
- Wadden TA, et al. Research on combining behavioral interventions with GLP-1 pharmacotherapy for weight management. NEJM. 2024.
Frequently Asked Questions
Found is generally less expensive than Sequence, though both bundle additional services (coaching at Found, dedicated provider continuity at Sequence) into pricing that's substantially higher than medication-focused specialists. Luma Health offers the same general category of compounded medication for $90/month (semaglutide) or $165/month (tirzepatide), well below both.
Yes. Both prescribe compounded semaglutide and compounded tirzepatide, the same active ingredients found in Wegovy and Zepbound. The pharmacology is identical regardless of which platform writes the prescription; the differences are in price, coaching philosophy, and provider continuity model.
Sequence's dedicated provider-team model may be better suited for patients with complex medical histories or multiple comorbidities, since the continuity of working with the same clinical team supports more nuanced, longitudinal dose management. Found's coaching-focused model is generally better suited for patients whose primary need is behavioral accountability rather than complex clinical oversight.
Yes. Start Luma Health's intake first and confirm your prescription is approved and shipping before canceling your current provider. Share your current dose and titration history so Luma Health's clinical team can continue your treatment at your established dose.
Research generally supports that structured behavioral interventions can modestly improve weight loss outcomes and maintenance when combined with GLP-1 pharmacotherapy. However, the medication itself drives the majority of weight loss in most patients, and the added benefit of behavioral coaching varies by individual engagement level and study design.